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Trial DesignA randomized trial to compare the safety of
rivaroxaban vs aspirin in addition to either
clopidogrel or ticagrelor in acute coronary
syndrome: The design of the GEMINI-ACS-1
phase II study
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reduction in ischemic events compared with aspirin monotherapy. The factor Xa inhibitor rivaroxaban was shown to be
associated with a significant reduction in the composite of cardiovascular death, myocardial infarction, and stroke, and
resulted in a nominal reduction in cardiovascular death, when added to background DAPT in the ATLAS ACS 2–TIMI 51 trial;
however, there was excessive bleeding with this “triple-therapy” approach. The combination of rivaroxaban with P2Y12
inhibition in a “dual-pathway” approach may be an effective therapeutic regimen for the treatment of ACS, given the known
importance of P2Y12 inhibition after stenting and intriguing data that the combination of an anticoagulant with clopidogrel
after stenting in patients with atrial fibrillation appears an attractive option to this patient population. GEMINI-ACS-1 is a
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Treatment of acute coronary syndrome
Dual antiplatelet therapy (DAPT) is central to the
European Society of Cardiology1,2 and American Heart
Association/American College of Cardiology3,4 practice
guidelines for the treatment for patients with acute
coronary syndrome (ACS).
Despite the use and development of novel more potent
P2Y12 inhibitors, the residual risk of recurrent ischemic
events remains unacceptably high, especially in the
medically managed patient population.5,6 To mitigate
this risk, a variety of “triple-”therapy approaches have
been explored; however, the addition of either another
antiplatelet agent (the protease-activated receptor-1
inhibitor vorapaxar) or oral anticoagulants at therapeutic
Table I. Comparison of ischemic and bleeding events in the
ATLAS ACS 2–TIMI 51 trial by treatment group
Rivaroxaban 2.5
mg twice daily
Rivaroxaban 5
mg twice daily Placebo
Composite of CV death,
MI, stroke
9.1 8.8 10.7
Death, MI, stroke 9.3 9.1 11.0
Cardiovascular death 2.7 4.0 4.1
Stent thrombosis 2.2 2.3 2.9
Non-CABG TIMI
major bleeding
1.8 2.4 0.6
TIMI minor bleeding 0.9 1.6 0.5
TIMI bleeding requiring
medical attention
12.9 16.2 7.5
Intracranial hemorrhage 0.4 0.7 0.2
Fatal bleeding 0.1 0.4 0.2
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Volume 174doses (apixaban,7 dabigatran,8 or darexaban9) was
associated with a higher bleeding risk and modest
nonstatistically significant impact on ischemic events.10
In contrast, the addition of rivaroxaban, at compara-
tively lower doses, to DAPT as explored in the Anti-Xa
Therapy to Lower Cardiovascular Events in Addition to
Aspirin with or without Thienopyridine Therapy in
Subjects with Acute Coronary Syndrome (ATLAS) pro-
gram was associated with a 31% relative risk reduction
(RRR) in the primary composite end point of cardiovas-
cular death, myocardial infarction (MI), and stroke in the
phase II ATLAS ACS-TIMI 46 trial.11 A clear dose-response
relationship between the total daily dose of rivaroxaban
and bleeding, coupled with a lack of greater efficacy at
higher doses on ischemic events led to the selection of
lower doses (2.5 and 5 mg twice daily) for assessment in a
phase III trial (ATLAS ACS 2–TIMI 51), which demon-
strated an RRR of 16% on ischemic events (24-month
Kaplan-Meier rate of 8.9 and 10.7, respectively) in the
combined rivaroxaban groups.12 In addition, a ~35%
reduction in cardiovascular (2.7% vs 4.1%; P = .002) and
all-cause (2.9% vs 4.5%; P = .002) mortality was observed
in the 2.5-mg arm. Given a dose-dependent bleeding
hazard and preservation of ischemic effectiveness in the
lowest-dose rivaroxaban arm (Table I), the European
Society of Cardiology guidelines for ST-segment elevation
MI (STEMI),2 non–ST-segment elevation (NSTE)–ACS,1
and myocardial revascularization13 suggest (level IIB) that
low-dose rivaroxaban (2.5 mg twice daily) may be
considered in addition to clopidogrel and aspirin in
appropriate patients.1
Alternative strategies: removing aspirin
Aspirin has been the cornerstone of treatment of
antithrombotic events since the initial demonstration of
a highly significant effect on mortality in patients with
both non-STEMI (NSTEMI) and STEMI.14–17Both theoretical and clinical findings suggest that
alternative dual antithrombotic approaches combining a
P2Y12 inhibitor with low-dose oral anticoagulation might
retain effectiveness against ischemic eventswhile reducing
the bleeding risk observed with triple or DAPT therapies.
First, although the use of a P2Y12 inhibitor after stenting
appears important to reduce acute ischemic complica-
tions,18 the risks and benefits of aspirin in this setting have
never been fully tested.
Second, the addition of a second antiplatelet agent adds
significant bleeding risk, and aspirin, with direct gastroin-
testinal toxicity, leads directly to increased bleeding. In the
STent Anticoagulation Restenosis Study (STARS), the addi-
tion of ticlopidine after percutaneous coronary intervention
(PCI) resulted in a 3-fold increase in hemorrhagic complica-
tions with rates of bleeding similar to a strategy using
full-dose warfarin,18 whereas the CURE trial demonstrated a
30% increase inmajor and a 2-fold increase inminor bleeding
with aspirin and clopidogrel comparedwith aspirin alone.19
Third, the benefit of aspirin in addition to P2Y12
inhibition remains unproven. The Management of ATh-
erothrombosis with Clopidogrel in High-risk patients
(MATCH) trial showed marked increases in minor, major,
and life-threatening bleeding with relatively small im-
provements in ischemic events when aspirin was added
to clopidogrel in patients with prior stroke.20
Finally, DAPT targets the action of products released
on platelet activation via interaction with collagen, but
does not inhibit direct platelet activation by potent
agonists such as thrombin, which is generated in
prothrombotic conditions such as MI (Figure 1).21–24
Rivaroxaban, by directly inhibiting factor Xa and
prothrombinase complex activity, prolongs the time
and suppresses the maximal extent of thrombin gener-
ation. In the ATLAS ACS-TIMI 46 trial, treatment with
rivaroxaban was associated with reduced thrombin
generation both acutely and at 6-month follow-up.25 In
an in vivo rat shunt thrombosis model, rivaroxaban and
clopidogrel were as effective as triple therapy and more
effective in suppressing thrombus formation than any
single agent, DAPT, or rivaroxaban and aspirin, while
demonstrating lower bleeding times than DAPT or triple
therapy.26 Finally, rivaroxaban and ticagrelor may act
synergistically to reduce platelet aggregation. In an in
vitro model, either agent alone resulted in 31% to 37%
inhibition of tissue factor–induced platelet aggregation;
however, the combination, even at submaximal dosing,
resulted in N90% inhibition.26 These observations
suggest that suppression of thrombin generation might
be particularly effective at limiting ischemic events via
both an anticoagulation effect as well as inhibition of
thrombin-mediated platelet activation.
Clinical trial results with dual-pathway inhibition.
Clinical findings support the hypothesis that dual anti-
thrombotic approaches warrant additional study. The
What is the Optimal antiplatElet and anticoagulant therapy
Figure 1
Sites of action of current antithrombotic therapies in patients with ACS. ASA and P2Y12 inhibitors inhibit the action of effectors released from
activated platelets. Inhibition of factor Xa prevents both direct thrombin activation of platelets and intracoronary thrombus formation.
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(WOEST) study compared the use of oral anticoagulation
and clopidogrel alone with triple therapy in patients with an
indication for oral anticoagulation after PCI. A dual-pathway
approachwas associatedwith a 64%RRR inbleeding (hazard
ratio [HR] 0.36, 95% CI 0.26-0.50, P b .001), and a lower rate
of ischemic end points (11.1% vs 17.6; HR 0.60, 95% CI
0.38-0.94, P = .025).27 These findings have spurred a variety
of trials exploring the utility of a dual-pathway strategy
without aspirin in patients with atrial fibrillation undergoing
PCI (Table II). To date, no safety concerns have been raisedTable II. Clinical trials exploring nonaspirin approaches to ACS or post-P
Trial Indication N Arm 1
WOEST27 AF + PCI 573 Warfarin + clopidogrel War
REDUAL-PCI28 AF + PCI 8520 Dabigatran 110 mg
BID + P2Y12 inhibitor
Dabi
AUGUSTUS29 AF + PCI 4600 Apixaban + P2Y12
inhibitor ± aspirin⁎
War
PIONEER AF-PCI30 AF + PCI 2125 Rivaroxaban 15 mg
QD + P2Y12 inhibitor
Riva
P2Y1
GLOBAL LEADERS31 PCI 16000 DAPT × 1-mo ticagrelor only DAP
TWILIGHT32 PCI 9000 DAPT × 3-mo ticagrelor only DAP
Abbreviations: AF, Atrial fibrillation; BID, twice daily; QD, once daily; VKA, vitamin K antag
⁎Study uses a 2 × 2 factorial design with randomization to apixaban vs warfarin and aspirin these trials.30 In addition, 2 other ongoing post-PCI studies
are comparing a ticagrelor alone approach with DAPT,
starting either 1 month31 or 3 months32 after PCI. Although
these trials will build on our understanding of the utility of
long-term DAPT,33,34 they do not address the addition of
alternative therapies after cessation of aspirin.
The GEMINI-ACS-1 clinical trial builds on these
preclinical and clinical observations to explore the
feasibility and safety of a dual antithrombotic strategy
(rivaroxaban 2.5 twice daily with a P2Y12 inhibitor) in
comparison with conventional DAPT (aspirin 100 mgCI treatments
Arm 2 Arm 3
farin + clopidogrel + aspirin –
gatran 150 mg BID + P2Y12 inhibitor VKA + P2Y12 inhibitor + aspirin
farin + P2Y12 inhibitor ± aspirin –
roxaban 2.5 BID + aspirin +
2 inhibitor
VKA + aspirin + P2Y12 inhibitor
T × 12 mo –
T × 12 mo –
onist.
in vs placebo.
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Volume 174daily with a P2Y12 inhibitor) for secondary prevention in
patients with recent ACS.Methods
Study overview
GEMINI-ACS-1 (NCT02293395) is a phase II, randomized,
double-blind, double-dummy, active-controlled study asses-
sing the safety and feasibility of rivaroxaban (2.5 mg twice
daily) and a P2Y12 inhibitor compared with conventional
DAPT (aspirin [100mg]+P2Y12 inhibitor) in patientswithin
10 days of an ACS event. The study will be conducted at
approximately 370 sites in 22 countries with proportional
geographic representation (Figure 2).
GEMINI-ACS-1 was designed by an academic executive
committee (Appendix A) comprising international experts
in interventional cardiology and thrombosis/hemostasis and
representatives from each of the sponsors. The executive
committee will oversee the medical, scientific, and opera-
tional conduct of the study, and reviewand approve analyses
for publication. A steering committee (Appendix A)
comprising the executive committee and individual country
leaders will provide feedback on country-specific issues
related to applicability of the trial and regional practices, and
formulate substudy analysis initiatives.
GEMINI-ACS-1 adheres fully to the ethical principles of the
Declaration of Helsinki, the specifications of the Internation-
al ConferenceonHarmonization, andGoodClinical Practice,
including the requirement for each subject's informed
consent before initiating any study procedure.Study population
GEMINI-ACS-1 will enroll approximately 3,000 patients
with recent (b10 days) ACS. Patients with unstable
angina, NSTEMI, and STEMI treated with medical therapy
alone, PCI, or coronary artery bypass graft (CABG)
surgery are eligible. Key inclusion and exclusion criteria
are shown in Table III. Notably, patients younger than 55
years must have diabetes or have had an MI prior to the
index presentation, and patients with NSTEMI or unstable
angina must fulfill enrichment criteria to ensure a
population at risk for future events.
Patients will receive at least 1 dose of DAPT with aspirin
and a P2Y12 inhibitor prior to randomization and, in
those undergoing PCI, an additional dose after PCI. All
patients should be intended to be treated with DAPT for
their ACS event and agree to provide a genetic sample for
CYP2C19 testing.
Randomization and treatment. Randomization will
be 1:1 stratified by intended P2Y12 inhibitor use
(clopidogrel 75 mg daily or ticagrelor 90 mg twice
daily), with approximately 1,500 patients in each P2Y12
inhibitor strata. The study will use a double-blind,
double-dummy design. Patients will be provided with
drug packs containing either aspirin (100 mg) ormatching placebo taken once daily, and rivaroxaban or
matching placebo taken twice daily. Dosing of aspirin
was based on analyses indicating either greater35 or
identical ischemic benefit but a bleeding hazard associ-
ated with higher aspirin dosing.36 All patients must
receive a dose of DAPT prior to randomization. Patients
undergoing PCI must receive 2 doses of DAPT, including
a minimum of 1 dose post-PCI. Patients post-CABG
surgery may be enrolled once able to tolerate DAPT,
but not within 12 hours of CABG surgery. Study drug will
be started on the day of randomization and will be taken
on a 12-hour schedule. All study drugs and P2Y12
inhibitors will be provided by the sponsor for the
duration of the study.
All patients will be treated for 12 months or until the
study treatment end date, defined as 180 days after the
last subject is randomized. At the end of the treatment
phase, or on permanent discontinuation of study drug, all
patients will be instructed to receive treatment with
aspirin (unless contraindicated) starting on the day after
the last dose of study drug. The duration of continued
background treatment with a P2Y12 inhibitor will be left
to the discretion of the managing physician, but it is
preferred that the P2Y12 treatment continues at least
until the end of study visit.
All outcomes (bleeding, death, MI, stroke, and stent
thrombosis) will be collected at days 30, 90, 180, 270, and
360, and at a study visit 30 days after permanent cessation of
study drug, either during or at the conclusion of the study.
Genomic evaluation. A pharmacogenomics sample
for assessment of CYP2C19 metabolizer status will be
obtained from all participants. The principal investigator
will be informed of genotyping results for all subjects
regardless of P2Y12 inhibitor choice (clopidogrel or
ticagrelor) and any prior CYP2C19 genotype testing, and
will inform subjects of the results. No instructions or
guidelines will be provided from study leadership on how
to interpret or use these results; however, investigators
will be asked to prespecify what actions they expect to
take with regard to P2Y12 inhibitor choice, and actual
action will subsequently be tracked.End points
The primary end point is Thrombolysis in Myocardial
Infarction (TIMI) clinically significant bleeding (major,
minor, or requiring medical attention). The primary
exploratory efficacy determination will be a composite of
cardiovascular death, MI, ischemic stroke, and stent
thrombosis. All ischemic and bleeding outcomes after
randomization will be adjudicated by an independent
clinical events committee (Appendix A), blinded to
treatment assignment, using previously published criteria
and recommended event definitions.37–41 Bleeding
events will be adjudicated based on TIMI, Bleeding
Academic Research Consortium, Global Use of Strategies
Figure 2
GEMINI-ACS-1 trial design.
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Society on Thrombosis and Haemostasis criteria. Unde-
termined deaths will be categorized as cardiovascular
deaths. Importantly, for this trial, all hemorrhagic deaths
will be categorized as cardiovascular deaths. Event
definitions are shown in Table IV.
Alterations in study treatment during conduct of the trial
Study treatment may be temporarily held if the patient:
a. undergoes PCI, CABG, or any other surgical procedure;
b. experiences a significant bleeding event;
c. develops a new neurologic deficit or alteration in
mental status;
d. develops a platelet count b50,000/μL;
e. has an adverse event related to or exacerbated by
study drug; or
f. requires anticoagulation or prohibited therapy on a
temporary basis.
In these cases, study drug can be resumed when deemed
safe by the investigator. If appropriate, open-label aspirin
may be used during this period. Patients should discontinue
treatment if they require open-label long-term anticoagula-
tion, have a transient ischemic attack or stroke, become
pregnant, develop critical bleeding or other adverse event
precluding further use, develop renal insufficiency (CrClb15
mL/min), or request to stop study drug.
In rare cases, it may be necessary to unblind treatment
assignment to allow proper medical treatment to be
administered (for instance, to dose other anticoagulants
during urgent procedures or thrombolysis). In such cases,
the investigator may contact the interactive Web
response system vendor to determine individual patientassignments. It is recommended that the investigator
contact the sponsor or its designee, if possible, to discuss
the particular situation before breaking the blind, and the
sponsor must be informed as soon as possible after
unblinding has occurred. Investigators will not disclose
treatment assignment to the subject whenever possible;
subjects who have had their treatment assignment
unblinded may continue on study drug if appropriate.
Concern over stent thrombosis and safety review
Dual antiplatelet therapy with aspirin and a P2Y12
inhibitor is the standard for prevention of acute
thrombotic complications since a series of trials com-
pared ticlopidine and aspirin with other anticoagulation
strategies.18,42–45 Several developments have altered this
landscape, including the development of novel oral
anticoagulants which reach therapeutic levels within
hours of administration and are not accompanied by an
initial prothrombotic state. In addition, the development
of more potent P2Y12 inhibitors, their routine earlier
administration in the treatment for ACS patients, and
newer less thrombogenic stent technologies have con-
tinued to impact post-PCI care since the completion of
the ATLAS trials.11,12 GEMINI-ACS-1 differs from many
trials in the early transition (1-10 days after presentation)
to a dual-pathway strategy using a single antiplatelet agent
post-ACS. Given that early cessation of DAPT has been
associated with a significant risk of stent thrombosis,46
the safety of this approach has yet to be established,
although it is reassuring that several studies incorporating
similar strategies have either completed enrollment or are
ongoing without evident safety concerns raised.30
To monitor and protect patient safety, GEMINI-ACS-1
will actively engage and use an independent data
Table III. Key inclusion and exclusion criteria
Inclusion criteria
Age ≥18 y
ACS within 48 h of hospitalization or while hospitalized
Receiving DAPT and plan to continue DAPT
If age b55 y, must have diabetes or MI prior to index event
Enrichment criteria
A. STEMI
• ECG criteria (1 of the following):
- ST-segment elevation N0.1 mV in 2 or more contiguous leads
- New LBBB
- ST-segment depression ≥0.1 mV in V1-V4 (posterior MI)
• Elevated cardiac biomarkers
B. NSTEMI
• Clinical symptoms of ACS + elevated cardiac biomarkers AND at
least 1 of the following:
1. ECG criteria
- Transient ST-segment elevation ≥0.1 mV
- New horizontal or down-sloping ST depression ≥0.05 mV
- New T-wave inversions ≥0.1 mB in 2 leads with prominent R
wave of t/s ratio N1
2. Identification of a culprit lesion by angiography
C. Unstable angina
• Clinical symptoms of ACS + elevated cardiac biomarkers AND at
least 1 of the following:
1. EKG criteria as listed above
2. Revascularization for the index event AND
3. TIMI risk score ≥4
Exclusion criteria
Prior stroke or TIA
Contraindication to anticoagulation including
• Active bleeding
• History of intracranial hemorrhage
• Clinically significant GI bleeding within 12 mo
• INR N1.5 or plt count b90,000/μL
Use of abciximab within 8 h, or eptifibatide or tirofiban within 2 h
Creatinine clearance b20 mL/min
Severe concomitant disease, including HIV, liver disease, life-limiting
conditions
Fibrinolytic therapy precludes enrolment in the ticagrelor stratum
Use of omeprazole or esomeprazole in the clopidogrel stratum
Need for chronic anticoagulation
Need for chronic nonsteroidal anti-inflammatory drug use
Unwilling to take contraceptive measures to prevent pregnancy (both sexes)
Abbreviations: ECG, Electrocardiogram; GI, gastrointestinal; HIV, human immuno-
deficiency virus; INR, international normalized ratio; LBBB, left bundle-branch block;
MI, MI; plt, platelet; TIA, transient ischemic attack.
Table IV. Bleeding and ischemic end points
leeding end points
IMI
• Major
- ≥5 g/dL drop in Hgb
- Intracranial hemorrhage
- Fatal hemorrhage
• Minor
- 3-4.9 g/dL drop in Hgb
• Requiring medical attention
- Medical or surgical treatment
• Life-threatening
- Fatal
- Need for IV inotropes
- Requires surgical intervention
- ≥4 U transfusion
- Symptomatic intracranial
TH
USTO
ARC
Ischemic end points
eath
• Cardiovascular
- MI
- Sudden cardiac death
- Stroke
- Heart failure
- Cardiovascular procedure
- Any hemorrhagic death
- Other
- Undetermined
• Noncardiovascular
troke
• Focal neurologic deficit N24 h
• Nonlocalizing or transient symptoms with imaging evidence of stroke
• Categorized as hemorrhagic, ischemic, or unknown
I (universal definition)
tent thrombosis (ARC definition)
bbreviations: ARC, Academic Research Consortium; BARC, Bleeding Academic
esearch Consortium; GUSTO, Global Use of Strategies to Open Occluded Coronary
rteries; Hgb, hemoglobin; ISTH, International Society on Thrombosis and Haemos-
sis; IV, intravenous.
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ford University, including experts in clinical trials,
interventional cardiology, thrombosis, and biostatistics.
The DMC chairman will review each definite and
probable stent thrombosis, death, and major bleeding
event as they are reported. The DMC is scheduled to
review data every 4 months throughout the enrollment
period. In addition, a DMC meeting may be convened
without notification of the sponsor or trial leadership.B
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taStatistical considerations
The primary objective of the study is to estimate
bleeding risk of rivaroxaban 2.5 mg twice daily compared
with aspirin 100 mg daily when added to background of
P2Y12 inhibition. A Cox proportional hazards model
from time of randomization to the first non–CABG
surgery-related TIMI clinically significant bleeding event
will be used for the primary analysis. Bleeding rates were
modeled based on the ATLAS ACS 2–TIMI 51 trial,
assuming 85 primary events per stratum, an incidence
rate of 4.5% at day 180 and 6.5% at day 360 in the aspirin
(DAPT) arm, and a discontinuation rate of 10% by day
126 Povsic et al
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April 2016360; an observed HR of 1.0 will result in an upper bound
of the 2-sided 95% CI of 1.5, whereas an observed HR of
1.3 will define an upper bound of 95% CI at 2.0. With 170
total events, an observed HR of 1.0 results in an upper
bound of the 95% CI of 1.4. The primary analysis will be
performed on the intention-to-treat population and will
include data through the end of study visit. The analysis
will be repeated on the as-treated population as the
primary safety analysis. All analyses will use data
adjudicated by the clinical events committee. An
exploratory efficacy analysis will investigate the time to
occurrence of the composite of cardiovascular death, MI,
stroke, and stent thrombosis, and each of these compo-
nents individually.
As a sensitivity analysis of the primary end point, a
P2Y12-stratified Cox proportional hazards model will be
conducted based on the intention-to-treat analysis set and
on-treatment analysis phase across strata. Homogeneity of
treatment effects between the clopidogrel and ticagrelor
strata will be explored via a test for treatment-by-stratum
interaction using the Cox proportional hazards model
with treatment, stratum, and the treatment-by-stratum
interaction as the covariates at a 2-sided significance level
of .05. If there is a statistically significant interaction,
clinical interpretations will be explored.
Additional post hoc analyses may be conducted to
investigate unexpected results, including the impact of
differential study drug discontinuations and/or differen-
tial discontinuation of P2Y12 between the 2 treatment
groups and between the 2 strata.
Summary
GEMINI-ACS-1 will assess the bleeding risk of a dual
antithrombotic therapy compared with conventional
DAPT in an ACS population, a substantial proportion of
which are expected to undergo PCI for their index event,
while monitoring for concerning signals around ischemic
events, specifically stent thrombosis.Acknowledgment
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